AVERROES Study Is Stopped Early, Results Show Apixaban Cuts Risk of Stroke
The AVERROES study compares Apixaban to Acetylsalicyclic Acid (Aspirin) to prevent strokes in patients with Atrial Fibrillation, specifically those who are not appropriate for Vitamin K Antagonist Treatment (Coumadin). Patients who were not candidates for warfarin therapy and began using Apixaban experienced a decreased risk of stroke and systemic embolism. Dr. Steven Shayani, Chairman of the New York Heart Research Foundation (NYHRF), was one of the principle investigators at the NYHRF for this study. “Based on analysis by the independent data monitoring committee, there was clear evidence of a clinically important reduction in stroke and systemic embolism,” Dr. Shayani explained. “This is great news for patients with Atrial Fibrillation who are intolerant or unsuitable for warfarin.” According to the New England Journal of Medicine, the trial was stopped prematurely because the results were overwhelmingly positive for Apixaban therapy in this specific group of patients. Apixaban is an oral factor Xa inhibitor and is used as an alternative treatment for patients who are not suitable candidates for warfarin, dabigatran, or rivaroxaban.